310 related articles for article (PubMed ID: 21800152)
1. Differential mRNA and tissue expression of lymphangiogenic growth factors (VEGF-C and -D) and their receptor (VEGFR-3) during tail regeneration in a gecko.
Blacker HA; Orgeig S
J Comp Physiol B; 2012 Jan; 182(1):109-26. PubMed ID: 21800152
[TBL] [Abstract][Full Text] [Related]
2. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
[TBL] [Abstract][Full Text] [Related]
3. Effects of acute exercise, exercise training, and diabetes on the expression of lymphangiogenic growth factors and lymphatic vessels in skeletal muscle.
Kivelä R; Silvennoinen M; Lehti M; Kainulainen H; Vihko V
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2573-9. PubMed ID: 17766486
[TBL] [Abstract][Full Text] [Related]
4. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
5. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
6. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
7. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.
Zhao W; Wang J; Zhu B; Duan Y; Chen F; Nian W; Sun J; Zhang B; Tong Z; Chen Z
Oncol Rep; 2016 Mar; 35(3):1483-92. PubMed ID: 26706909
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of lymphangiogenic markers in human gastroenteric tumor.
Yuanming L; Feng G; Lei T; Ying W
Arch Med Res; 2007 Jan; 38(1):106-12. PubMed ID: 17174733
[TBL] [Abstract][Full Text] [Related]
9. Roles of the TGF-β⁻VEGF-C Pathway in Fibrosis-Related Lymphangiogenesis.
Kinashi H; Ito Y; Sun T; Katsuno T; Takei Y
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142879
[TBL] [Abstract][Full Text] [Related]
10. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
11. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes.
Kitadai Y; Kodama M; Cho S; Kuroda T; Ochiumi T; Kimura S; Tanaka S; Matsumura S; Yasui W; Chayama K
Int J Cancer; 2005 Jun; 115(3):388-92. PubMed ID: 15688374
[TBL] [Abstract][Full Text] [Related]
13. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread.
Schneider M; Büchler P; Giese N; Giese T; Wilting J; Büchler MW; Friess H
Int J Oncol; 2006 Apr; 28(4):883-90. PubMed ID: 16525637
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of lymphangiogenic markers in human colorectal cancer.
Parr C; Jiang WG
Int J Oncol; 2003 Aug; 23(2):533-9. PubMed ID: 12851706
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Eroğlu A; Ersöz C; Karasoy D; Sak S
Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
[TBL] [Abstract][Full Text] [Related]
16. Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1.
Jha SK; Rauniyar K; Karpanen T; Leppänen VM; Brouillard P; Vikkula M; Alitalo K; Jeltsch M
Sci Rep; 2017 Jul; 7(1):4916. PubMed ID: 28687807
[TBL] [Abstract][Full Text] [Related]
17. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.
Garrafa E; Caprara V; Di Castro V; Rosanò L; Bagnato A; Spinella F
Life Sci; 2012 Oct; 91(13-14):638-43. PubMed ID: 22552325
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-8: A potent promoter of human lymphatic endothelial cell growth in gastric cancer.
Shi J; Li YJ; Yan B; Wei PK
Oncol Rep; 2015 Jun; 33(6):2703-10. PubMed ID: 25891418
[TBL] [Abstract][Full Text] [Related]
20. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
